Search
Fluocinolone
go.drugbank.com/drugs/DB12553InvestigationalFluocinolone has been used in trials studying the treatment and prevention of Candida Infection, Oral Lichen Planus, Macular Degeneration, and Choroidal Neovascularization.
Ebselen
go.drugbank.com/drugs/DB12610InvestigationalEbselen has been investigated for the treatment and basic science of Meniere's Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus.
Samatasvir
go.drugbank.com/drugs/DB12660InvestigationalSamatasvir has been used in trials studying the treatment of Hepatitis C, Chronic, Chronic Hepatitis C Virus, and Chronic Hepatitis C Infection.
Naptumomab estafenatox
go.drugbank.com/drugs/DB12807InvestigationalNaptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.
Pyroxamide
go.drugbank.com/drugs/DB12847InvestigationalPyroxamide has been used in trials studying the treatment of Leukemia, Lymphoma, Small Intestine Cancer, Precancerous Condition, and Myelodysplastic Syndromes, among others.
Ombrabulin
go.drugbank.com/drugs/DB12882InvestigationalOmbrabulin has been used in trials studying the treatment of Sarcoma, Neoplasms, Solid Tumor, Neoplasms, Malignant, and Advanced Solid Tumors, among others.
Samarium Sm-153
go.drugbank.com/drugs/DB12905InvestigationalSamarium 153 has been used in trials studying the supportive care of Pain, Lung Cancer, Breast Cancer, Prostate Cancer, and Metastatic Cancer.
EB05
go.drugbank.com/drugs/DB16477InvestigationalEB05, in combination with standard of care (SOC), is being investigated in clinical trial NCT04401475 to evaluate its safety and efficacy in adult hospitalized patients with COVID-19 and ARDS.
AI-850
go.drugbank.com/drugs/DB05842ExperimentalAI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.
Stannsoporfin
go.drugbank.com/drugs/DB04912InvestigationalStannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing